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We aimed to evaluate the efficacy of a new combination antiemetic therapy comprising aprepitant, 
granisetron, and dexamethasone in gastric cancer patients undergoing chemotherapy with cisplatin and 
S-1. 
Methods 
Gastric cancer patients scheduled to receive their first course of chemotherapy with cisplatin (60 mg/m2) 
and S-1 (80 mg/m2) were treated with a new combination antiemetic therapy aprepitant, granisetron, and 
dexamethasone on Day 1; aprepitant and dexamethasone on Days 2 and 3; and dexamethasone on Day 4. 
The patients reported vomiting, nausea, use of rescue therapy, and change in the amount of diet intake, 
and completed the Functional Living Index-Emesis (FLIE) questionnaire. The primary endpoint was 
complete response (CR; no emesis and use of no rescue antiemetics) during the overall study phase 
(0-120 h after cisplatin administration). The secondary endpoints included complete protection (CP; CR 
plus no significant nausea); change in the amount of diet intake; and the impact of 
chemotherapy-induced nausea and vomiting (CINV) on daily life during the overall, acute (0-24 h), and 
delayed (24-120 h) phases. 
Results 
Fifty-three patients were included. CR was achieved in 88.7%, 98.1%, and 88.7% of patients in the 
overall, acute, and delayed phases, respectively. The corresponding rates of CP were 67.9%, 96.2%, and 
67.9%. Approximately half of the patients had some degree of anorexia. FLIE results indicated that 
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79.5% of patients reported “minimal or no impact of CINV on daily life”. 
Conclusions 
Addition of aprepitant to standard antiemetic therapy was effective in gastric cancer patients undergoing 
treatment with cisplatin and S-1. 
 





Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event observed in more than 
90% of patients treated with highly emetogenic antitumor agents [1]. CINV is one of the greatest fears 
of patients beginning chemotherapy [2, 3]. Inadequate control of CINV can lead to dehydration, 
malnutrition, and electrolyte imbalance. These symptoms impair functional activity and quality of life 
(QOL) of patients, increase the use of healthcare resources, and may occasionally cause treatment delay 
or discontinuation [4-6]. 
Generally, CINV persists approximately for 5 days after administration of emetogenic antitumor agents. 
CINV occurring within the first 24 h has been defined as acute and that occurring after more than 24 h 
as delayed [7]. The incidence and severity of CINV are affected by a number of factors, including the 
chemotherapeutic regimen-related factors such as the agent, dose, and schedule and patient-related 
factors such as age, sex, and history of alcohol use [8]. Of all the known predictive factors for CINV, the 
dose and intrinsic emetogenicity of a given chemotherapeutic agent are the important factors [9, 10]. 
Cisplatin, one of the strongest emetogenic antitumor agents, can cause both acute and delayed emesis. 
The incidence of CINV induced by cisplatin is 98% in the acute phase and 77% in the delayed phase 
after administration of ≥50 mg⁄m2 of cisplatin without preventive treatment [11]. 
Corticosteroids have been used as effective antiemetic agents for CINV for a long time [12]. They are 
effective for both acute and delayed emesis. The introduction of selective serotonin 
(5-hydroxytriptamine-3, [5-HT3]) receptor antagonists (RA) revolutionized the control of CINV. 
5-HT3RAs are used for moderate to highly emetogenic chemotherapy, and these agents exert protective 
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effects mainly in acute emesis. Although combination of corticosteroids and 5-HT3RA has been used as 
standard therapy for management for CINV, more than 50% of patients continue to vomit in response to 
highly emetogenic chemotherapy such as high-dose cisplatin [13]. This combination therapy prevents 
vomiting in the acute phase, but appears to lack efficacy in the delayed phase [14-16].  
The neurokinin-1 (NK1)RA represents the newest class of antiemetic agents for the prevention of CINV. 
NK1 receptors regulate the vomiting reflex, which is predominant during delayed phase [17]. Aprepitant, 
a new selective NK1RA, was the first available agent in this class, dramatically prevented CINV. 
Prospective phase III trials performed using highly emetogenic chemotherapy led to the approval of 
aprepitant [18-20]. In each trial, addition of aprepitant to the standard antiemetic therapy, 5-HT3RA and 
corticosteroid, controlled emesis by further 15 to 20%. 
The availability of new antiemetic agents has contributed to substantial improvements in control of 
emesis. A single agent cannot provide complete protection against various phases of emesis, while a 
combination of antiemetic agents such as NK1RA and 5-HT3RAs and corticosteroids can result in better 
prevention of CINV. Recently, several groups such as the Multinational Association of Supportive Care 
in Cancer (MASCC)/the European Society for Medical Oncology (ESMO), the American Society of 
Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN) have published 
and updated international antiemetic guidelines [8, 21, 22]. In 2010, Japanese Society of Clinical 
Oncology (JSCO) also published the antiemetic guideline [23]. They recommend the use of NK1RAs in 




Gastric cancer is one of the major causes of cancer death worldwide, and chemotherapy is the main 
treatment option for patients with advanced gastric cancer. To date, cisplatin plus fluoropyrimidine is a 
standard chemotherapeutic regimen for advanced gastric cancer, which definitely induces CINV. In the 
SPIRITS trial, a large phase III trial of cisplatin plus S-1 (an orally administrated 5-fluorouracil analog) 
for advanced gastric cancer, emesis occurred in 36% of patients and nausea in 67% of patients [24]. 
No studies have been performed with the new standard antiemetic regimen with a focus on gastric 
cancer patients treated with cisplatin-based chemotherapy. Some issues about the approval of aprepitant 
for patients with gastric cancer remain to be addressed. First, no study on CINV has been performed 
with a focus on gastric cancer. Furthermore, although the standard dose of cisplatin in S-1 plus cisplatin 
chemotherapy for gastric cancer is 60 mg/m2, the dose administered to gastric cancer patients in 
previous studies was ≥70 mg/m2 [18-20]. Therefore, the need for aprepitant is not known. Therefore, we 
performed a prospective observational study to evaluate the efficacy of a combination antiemetic 
therapy with aprepitant, granisetron, and dexamethasone in Japanese gastric cancer patients undergoing 
an initial chemotherapy cycle with cisplatin plus S-1. In addition, to our knowledge, no previous studies 
have reported the incidences of CINV in the initial cycle of chemotherapy, the incidence and degree of 
anorexia, and the impact of CINV on QOL with a focus on gastric cancer. Our results may be point of 





This study was a multi-institutional, prospective, observational, non-comparative study involving 17 
institutions of the Digestive Disease Support Organization (DDSO). We performed an observational 
study because a 3-drug combination therapy involving aprepitant is the recommended antiemetic 
prophylaxis in patients receiving cisplatin-based chemotherapy. Patients gave written informed consent. 
The protocol was approved by the institutional review board at each participating center, and the study 
was performed in accordance with the principles of the Declaration of Helsinki. (Clinical trial ID: 
UMIN000004175) 
Eligibility criteria 
High or moderate emetogenic chemotherapy-naive patients who were scheduled to receive their first 
course of chemotherapy with cisplatin (60 mg/m2) and S-1 (80 mg/m2) for pathologically confirmed 
gastric cancer were eligible. Patients were required to be ≥20 years of age and to have an Eastern 
Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. Patients with any vomiting, 
retching, or nausea (National Cancer Institute [NCI] ≥ grade I) 24 h before treatment or those using any 
drug with potential antiemetic efficacy in the 48 h before chemotherapy were ineligible. In addition, 
exclusion criteria included the following: radiation therapy to the abdomen or pelvis any time 1 week 
before treatment, a symptomatic primary or metastatic central nervous system (CNS) malignancy, a risk 
of vomiting for other reasons (epilepsy, active peptic ulcer, and gastrointestinal obstruction), and any 





All patients received S-1 plus cisplatin therapy according to SPIRITS trial [24]; S-1 plus cisplatin is the 
standard chemotherapeutic regimen for advanced gastric cancer in Japan. S-1 (80 mg/m2) was 
administered orally twice daily for the first 3 weeks of a 5-week cycle. Cisplatin was administered as an 
intravenous infusion of 60 mg/m² on day 8 of each cycle.  
Antiemetic treatment 
All patients received the following antiemetics: oral aprepitant 125 mg 60 min before cisplatin infusion 
plus intravenous dexamethasone 9.9 mg and intravenous granisetron 3 mg 30 min before cisplatin 
infusion on Day 1, oral aprepitant 80 mg once daily each morning and oral dexamethasone 8 mg bid on 
Days 2 and 3, and oral dexamethasone 8 mg bid on Day 4. This combination of antiemetics is 
recommended in JSCO Guidelines for Antiemetics in Oncology 2010 [23]. Patients were given a 
prescription for a rescue antiemetic to be used only when nausea and vomiting developed during the 
120-h observation period. 
Response definitions 
The observation period was divided in 3 distinct phases: acute, 0 to 24 h; delayed, 24 to 120 h; and 
overall, 0 to 120 h after injection of cisplatin. During the 120-h assessment period after the initiation of 
cisplatin infusion, patients were required to maintain a diary and record the number and timing of any 
episodes of vomiting or retching; the frequency and timing of use of rescue antiemetics; and the degree of 
nausea using a 4-point categorical scale (0, none; 1, mild; 2, moderate; 3, severe). Volume changes of diet 
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intake were recorded by patients every day on Days 1 to 5 as % volume of diet after treatment compared 
to that before the initiation of chemotherapy as baseline. Patients responded to the Functional Living 
Index-Emesis (FLIE) questionnaire once a day from Days 1 to 5, which captured information about the 
effect of CINV on the daily lives of the patients. 
The primary endpoint was the proportion of patients achieving CR (defined as no emesis and no rescue 
antiemetics use) during the overall study phase. No vomiting was defined as no vomiting, retching, or dry 
heaves. Secondary endpoints included the rate of CP (meet criteria for CR plus no significant nausea 
[nausea score, 0 and 1, nausea that does not interfere with the normal activities of the patient]); volume 
change of diet intake; no vomiting; no nausea; the impact of CINV on daily life (as measured by a FLIE) 
during the overall, acute, and delayed phases.  
The FLIE instrument is a patient-completed multidimensional questionnaire to evaluate the QOL [25]. 
Japanese version of the FLIE was used in this study, which was reported useful in assessing the impact of 
CINV on the QOL of Japanese patients [26]. The FLIE questionnaire contains a validated 18-item visual 
analogue scale (VAS)-based, patient-reported outcome measure that captures information about the effect 
of CINV on the daily lives of the patients. FLIE has separate domains for the impact of nausea and 
vomiting on the daily function of patients. Each item is answered using a 1- to 7-point VAS. Each item 
scales from 7 to 1(“not at all” to “a great deal”). Average score >6 points; total score >108 out of a 
maximum possible 126 points; each domain score >54, defined as “minimal or no impact of CINV on 
daily life.” 
Safety was evaluated on the basis of physical examination, including vital signs, routine clinical 
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laboratory tests, and adverse event reporting. Toxicity grades were assessed using the NCI Common 
Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0. 
(http://ctep.cancer.gov/forms/CTCAEv4.pdf). The adverse events were determined by the investigator to 
be possibly, probably, or definitively related to the study drug. 
Statistical analysis 
The incidence of CINV in the target population of this study is not clear; therefore, no definitive reference 
is available to calculate the standard deviation and sample size. In previous studies using aprepitant, the 
rates of CR were improved by approximately 20% after the addition of aprepitant to standard therapy. 
The SPIRITS trial showed that emesis was observed in 36% of patients, and nausea was observed in 67% 
(Grade 3/4, 11%) of patients. The incidence of emesis and nausea requiring treatment was assumed about 
50%, which accounted for 36% (emesis) plus 11% (Grade 3/4 nausea). To set an expected CR rate of 
70% and a threshold CR rate of 60%, a sample size of 50 subjects was estimated to be required to provide 
a power of 80% assuming a two-sided test and an overall significance level of 0.05. Assuming that 







Between January 2011 and May 2012, 56 patients were enrolled at 13 centers in Japan. Of the 56 
patients, 53 satisfied the eligibility criteria; the 3 patients who were excluded did not receive cisplatin 
injection, and they were included in the efficacy analyses. The basic characteristics of the patients are 
described in Table 1. Most patients were men (90.6%), and the median age of the patients was 65 years. 
Antiemetic outcome 
Antiemetic outcome is shown in Figure 1 and Table 2. The primary endpoint of CR for the overall study 
phase was achieved in 47 (88.7%) patients. Acute and delayed CR rates were 98.1% (52/53) and 88.7% 
(47/53), respectively. These results were considerably superior to the expected CR rate of 70%. CP rates 
for the overall, acute, and delayed study phases were 67.9% (36/53), 96.2% (51/53), and 67.9% (36/53), 
respectively. “No vomiting” rates for the overall, acute, and delayed study phases were 92.5% (49/53), 
98.1% (52/53), and 92.5% (49/53), and “No nausea” rates for the overall, acute, and delayed study 
phases were 64.1% (34/53), 92.4% (49/53), and 66.0% (35/53), respectively. Overall, 19 (35.9%) 
patients experienced some degree of nausea; mild nausea in 11 (20.8%) patients, moderate nausea in 7 
(13.2%) patients, and severe nausea in 1 (1.9%) patient. 
Assessment of the QOL (Table 3) 
Of the 53 eligible patients, 49, 50, and 49 patients answered the FLIE questionnaire in the overall, acute, 
and delayed phases, respectively. In the overall period of 5 days, 39 patients (79.5%) had a total FLIE 
score of more than 108, and 37 (75.5%) and 44 (89.8%) patients, respectively, had a nausea domain 
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score and vomiting domain score of more than 54, and reported “minimal or no impact of CINV on daily 
life.” Further, in the acute phase, 49 patients (98.0%) had a total FLIE score of more than 108, and 48 
(96.0%) and 50 (100%) patients, respectively, had a nausea domain score and vomiting domain score of 
more than 54, and reported “minimal or no impact of CINV on daily life.” Finally, in the delayed phase, 
39 patients (79.5%) had a total FLIE score of more than 108, and 37 (75.5%) and 44 (89.8%) patients, 
respectively, had a nausea domain score and vomiting domain score of more than 54, and reported 
“minimal or no impact of CINV on daily life.  
Diet intake (Figure 2) 
Approximately half of the patients had some degree of anorexia, and the decrease in oral intake was 
predominant in the delayed phase. Volume of diet intake was reduced to half in 30% of patients; in 
addition, 10% of the patients could not consume any food and beverage in the delayed phase. 
Safety 
Overall, antiemetic therapy was well-tolerated. Adverse events considered by the investigator to be 
possibly, probably, or definitely related to the study drug were anorexia in 7 (13.2%) patients, diarrhea in 
4 (7.5%) patients;, hiccups in 3 (5.7%) patients, and constipation in 1 (1.9%) patient. No serious adverse 





We have reported the results of prospective phase III trials performed using highly emetogenic 
chemotherapy that led to the approval of aprepitant [18-20]. Hesketh PJ and colleagues found that 
compared to the standard regimen, addition of aprepitant to the standard regimen improved the CR rates 
in overall (52% versus 72%), acute (78% versus 89%), and delayed phases (55% versus 75%) [18]; 
similarly, Poli-Bigelli and colleagues reported enhanced CR rates, in overall (43% versus 62%), acute 
(68% versus 82%), and delayed phases (46% versus 67%), respectively [19]. Schmoll HJ and 
co-workers showed that the CR rates were higher after addition of aprepitant in the overall (72% versus 
61%), acute (88% versus 79%), and delayed phases (74% versus 63%) [20]. These results indicate that 
addition of aprepitant had an obvious therapeutic advantage. 
Our study included a cohort of patients with solid cancer, who were scheduled to receive the 
chemotherapy containing cisplatin ≥70 mg/m2. The standard chemotherapy for advanced gastric cancer in 
Japan is 60 mg/m2 cisplatin; however, to our knowledge, no study has reported the efficacy of cisplatin 
plus S-1 therapy in a gastric cancer patient. In the SPIRITS trial, a large phase III trial of cisplatin plus 
S-1 for advanced gastric cancer, emesis occurred in 36% of patients and nausea in 67% of patients [24]. A 
large population of patients has CINV. Therefore, we performed this observational study to evaluate the 
efficacy of a new combination antiemetic therapy involving addition of aprepitant to the standard 
antiemetic therapy, focusing on Japanese patients with gastric cancer who received an initial cycle of 
cisplatin plus S-1.  
In the present study, a combination of aprepitant and granisetron and dexamethasone (recommended 
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regimen according to JSCO Guidelines for Antiemetics in Oncology 2010 [23]) showed that CR ratios 
were 88.7%, 98.1%, and 88.7% in patients in the overall, acute, and delayed phases, respectively. 
Approximately 90% of patients with gastric cancer receiving an initial cycle of cisplatin plus S-1 
chemotherapy were free from emesis. This result is similar to that of other aprepitant-containing 
antiemetic studies. The imbalance of male-to-female ratio was occurred in this study unexpectedly, the 
sample size of the study may affect the imbalance of gender. Although the patients in our study were 
biased towards male gender and elderly patients resistant to CINV, the results our study were excellent.  
CP rates were 67.9%, 96.2%, and 67.9% in patients in the overall, acute, and delayed phases, 
respectively. Control of nausea was not achieved in approximately 30% patients in the delayed phase; 
therefore, nausea was not as well-controlled as vomiting. These results indicate that this triple-drug 
combination therapy is not effective in controlling nausea in the delayed phase. Generally, clinicians 
underestimate the incidence of nausea, which is not as well-controlled as vomiting. Clinicians should 
pay more attention to nausea. 
We use the FLIE questionnaire to assess the patient-reported impact of CINV on the QOL [25]. In this 
study, results of the FLIE questionnaire showed that a high percentage of patients reported “minimal or 
no impact of CINV on daily life.” A reduction in the QOL was observed in approximately 20% more 
patients; the score in the nausea domain was inferior to the score in the vomiting domain, and the score 
in delayed phase was inferior to the score in the acute phase. The principal reason for reduction in the 




Moreover, approximately half of the patients showed a reduction in dietary intake, particularly in the 
delayed phase. Generally, loss of oral intake was considered as a symptom interrelated with the degree 
of nausea. In this study, the rate of anorexia was higher than the incidence of nausea. Loss of oral intake 
is thought to be the result of several distresses such as nausea, appetite loss, and decline in motivation to 
eat correlated with chemotherapy. Malnutrition in cancer patients affects the overall condition 
of the patient; it increases the number of complications and adverse effects 
of chemotherapy and reduces the QOL. Therefore, control of anorexia is an important 
consideration. 
Aprepitant used in combination with standard antiemetic therapy (5-HT3RA and corticosteroid) was 
well-tolerated and very effective in preventing CINV; therefore, it should be considered as a new standard 
of antiemetic prophylaxis for patients with gastric cancer treated with cisplatin plus S-1 chemotherapy. 
Although aprepitant is an important in controlling CINV, uncontrolled vomiting and inadequately 
controlled nausea continue to be the major problems in some patients. It is noteworthy that 30% of 
patients had uncontrolled nausea and half of the patients had anorexia in our study. The NK1RA may 
have less impact on the nausea component of CINV. Further improvement in the prevention of CINV will 
require more effective anti-nausea treatments. The control of nausea does not take precedence over the 
control of vomiting because the physiology of nausea is not well-understood [27] and the difficulty in 
measuring this subjective symptom; patients confuse nausea with anorexia, fatigue, or pyrosis [3]. 
Palonosetron, the second-generation 5-HT3RA differs from the older 5-HT3RAs in its prolonged half-life 
(approximately 40 h) and its substantially greater binding affinity for the 5-HT3 receptor [28]. It is a 
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potent 5-HT3RA that is more favorable compared to the first-generation 5-HT3RAs in terms of 
effectiveness and safety. Moreover, palonosetron specifically improves nausea control [29]. Thus, the 
question that whether palonosetron should be the preferred 5-HT3 RA when aprepitant is used should be 
addressed. To date, limited information is available about the combination of palonosetron and aprepitant 
[30-32]. The newest combination antiemetic therapy with palonosetron and aprepitant plus corticosteroid 
may lead to further improvement in the control of CINV. We performed this study for confirming the 
effect of the newest combination antiemetic therapy on CINV in gastric cancer patients receiving cisplatin 
plus S-1 chemotherapy. 
Despite limited sample size, our study has several important results. New combination antiemetic therapy 
involving addition of aprepitant to the standard antiemetic therapy was effective in Japanese patients with 
gastric cancer who received an initial cycle of cisplatin plus S-1. CINV was controlled as indicated by the 
result that a majority of the patients maintained their QOL. Our results indicate that this antiemetic 
regimen should be a recommended therapy for this population. Despite this effective antiemetic 
prophylaxis, there was room for improvement in controlling nausea and anorexia; therefore, further 
therapeutic intervention is required. In addition, our results indicate the incidences of CINV, particularly 
in patients receiving an initial cycle of chemotherapy; the incidence and degree of anorexia; the impact of 
CINV on the QOL of gastric cancer patients receiving chemotherapy. Our result serves as a useful 
benchmark for future studies on CINV. 
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Figure 1 - Percentage of patients with complete response (CR) and complete protection (CP).  
CR for the overall, acute, and delayed phases was achieved in 88.7%, 98.1%, and 88.7% of patients. CP 
rates for the overall, acute, and delayed phases were 67.9%, 96.2%, and 67.9%, respectively. 
Figure 2 - Decrease in diet intake compared to that before initiation of chemotherapy. 
Approximately half of the patients had some degree of anorexia; the decrease in oral intake was 
predominant in the delayed phase. 
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Table 1. Patient characteristics   
 
Characteristics  Number of patients 
All  53 
Age (range, 50 to 81 years; median, 65 
years) 
-65:66- 29:24 
Gender Male:Female 48:5 
Performance status 0:1 36:17 
Clinical stage of gastric cancer (TNM) II:III: IV:recurrence 2:13:23:14 
Alcoholic drinks None:several times:almost daily 25:5:23 
History of chemotherapy negative:positive 14:39 
History of chemotherapy-induced 
nausea and vomiting (CINV) 
negative:positive 53:0 
History of morning sickness negative:positive 52:1 
History of motion sickness negative:positive 52:1 
 
 
Table 2. Percentage of patients who achieved efficacy endpoint 
 
 Overall (0-120 h) Acute (0-24 h) Delayed (24-120 h) 
Complete response 88.7% 98.1% 88.7% 
Complete protection 67.9% 96.2% 67.9% 
No use of rescue therapy 96.2% 100% 96.2% 
No vomiting 92.5% 98.1% 92.5% 
No nausea 64.1% 92.4% 66.0% 
No significant nausea 69.8% 98.1% 69.8% 
 
 





Overall (0-120 h)  Acute (0-24 h)  Delayed (24-120 h) 
Number of patients  
% 
Number of patients  Number of patients  
Total NIDL  Total NIDL %  Total NIDL % 
FLIE total score 49 39 79.5  50 49 98.0  49 39 79.5 
nausea domain total score 49 37 75.5  50 48 96.0  49 37 75.5 
vomiting domain total score 49 44 89.8  50 50 100  49 44 89.8 
NIDL, No or minimal impact on daily life. Defined as domain total FLIE score of more than 54 or total FLIE score more 
than 108 
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